drugset / Trial / NCT00743002
A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione
RandomizedParallel-groupTriple-blindTreatment
Summary
This trial is designed to show the effect of treatment with TT223 or placebo on blood glucose control after 12 weeks of treatment with a 6 month follow-up. TT223 is administered by injection once daily to patients currently treated with Metformin and/or Thiazolidinedione.
Timeline
- Start
- 2008-08
- Primary completion
- 2009-12
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TT223 | Unknown | 3 mg | Subcutaneous |
| Background | Metformin | Small molecule | — | — |